BioMarin Pharmaceutical Inc. Announces Discontinuation of Certain Phase 2 VOXZOGO Trials
Key Points for Investors:
- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has announced the discontinuation of dosing and enrollment in its Phase 2 trials for VOXZOGO in Turner Syndrome, SHOX-deficiency, and Aggrecan (ACAN)-deficiency.
- The decision follows the occurrence of slipped capital femoral epiphysis (SCFE) events in two ongoing investigator-sponsored trials. SCFE is a rare but serious orthopedic condition, especially concerning in pediatric populations.
- Importantly, SCFE events have not been observed in BioMarin’s own Phase 2 trials for these same conditions, nor in trials involving children with Idiopathic Short Stature (ISS) without ACAN-deficiency.
- BioMarin will continue its Phase 2 CANOPY trials of VOXZOGO in children with Noonan syndrome and in those with ISS without ACAN-deficiency (which represents about 95% of children enrolled in the ISS trial).
Potentially Price-Sensitive Information:
- The discontinuation of three Phase 2 trials for VOXZOGO in Turner Syndrome, SHOX-deficiency, and ACAN-deficiency is a significant development, as it may impact BioMarin’s future revenue streams and growth prospects in these indications.
- This decision could affect investor sentiment, particularly as VOXZOGO is a key asset for BioMarin and any safety concerns or regulatory setbacks may trigger share price volatility.
- BioMarin’s continued trials in Noonan syndrome and ISS without ACAN-deficiency signal that the company still sees opportunity in these areas, but the setback in other indications may overshadow near-term optimism.
- BioMarin uses its investor relations website (https://investors.biomarin.com) for material disclosures and compliance with Regulation FD. Investors should monitor this site for future updates.
Additional Details:
- The company formally announced the change on March 16, 2026, in a Current Report on Form 8-K.
- BioMarin’s filings indicate that these forward-looking statements involve risks and uncertainties, including clinical trial results, regulatory decisions, and other factors detailed in their annual and subsequent SEC filings.
- BioMarin expressly disclaims any obligation to update forward-looking statements, which means investors should be cautious about relying on projections or expectations.
- The company’s Executive Vice President and Chief Legal Officer, G. Eric Davis, signed the report.
What Shareholders Need to Know:
- Safety events in clinical trials, especially those leading to the discontinuation of studies, are highly relevant to investors and may have a direct impact on BioMarin’s valuation.
- The company’s continued commitment to VOXZOGO in other indications suggests ongoing R&D investment, but also highlights the inherent risks in drug development.
- Shareholders should carefully review BioMarin’s risk disclosures and monitor future updates, as regulatory and clinical developments are likely to drive near-term share price movements.
Disclaimer:
This article is for informational purposes only and does not constitute investment advice. The information is based on BioMarin Pharmaceutical Inc.’s public filings and announcements as of March 16, 2026. Investors should conduct their own research and consult their financial advisors before making any investment decisions. BioMarin’s forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those projected. The company expressly disclaims any obligation to update these statements as a result of new information, future events, or otherwise.
View BIOMARIN PHARMACEUTICAL INC Historical chart here
